JP2012504133A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504133A5 JP2012504133A5 JP2011529267A JP2011529267A JP2012504133A5 JP 2012504133 A5 JP2012504133 A5 JP 2012504133A5 JP 2011529267 A JP2011529267 A JP 2011529267A JP 2011529267 A JP2011529267 A JP 2011529267A JP 2012504133 A5 JP2012504133 A5 JP 2012504133A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- group
- pharmaceutically acceptable
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 14
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 11
- 229940125833 compound 23 Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 10
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims 7
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims 7
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 6
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims 6
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 6
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 6
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims 6
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 claims 6
- 229940126142 compound 16 Drugs 0.000 claims 6
- 229940126208 compound 22 Drugs 0.000 claims 6
- 229940125851 compound 27 Drugs 0.000 claims 6
- 208000026278 immune system disease Diseases 0.000 claims 5
- 206010040047 Sepsis Diseases 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 claims 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 claims 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 2
- 229940126657 Compound 17 Drugs 0.000 claims 2
- 229940126639 Compound 33 Drugs 0.000 claims 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 229940125773 compound 10 Drugs 0.000 claims 2
- 229940125797 compound 12 Drugs 0.000 claims 2
- 229940126543 compound 14 Drugs 0.000 claims 2
- 229940125758 compound 15 Drugs 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- 229940125810 compound 20 Drugs 0.000 claims 2
- 229940126086 compound 21 Drugs 0.000 claims 2
- 229940125961 compound 24 Drugs 0.000 claims 2
- 229940125846 compound 25 Drugs 0.000 claims 2
- 229940127204 compound 29 Drugs 0.000 claims 2
- 229940126214 compound 3 Drugs 0.000 claims 2
- 229940125877 compound 31 Drugs 0.000 claims 2
- 229940125878 compound 36 Drugs 0.000 claims 2
- 229940125807 compound 37 Drugs 0.000 claims 2
- 229940127573 compound 38 Drugs 0.000 claims 2
- 229940125898 compound 5 Drugs 0.000 claims 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 0 C(CNCc1ccc(CN2CCOCC2)cc1)COc(cc1)ccc1C(Oc1c2)=*Cc1ccc2OCCCNCc1ccc(CN2CCOCC2)cc1 Chemical compound C(CNCc1ccc(CN2CCOCC2)cc1)COc(cc1)ccc1C(Oc1c2)=*Cc1ccc2OCCCNCc1ccc(CN2CCOCC2)cc1 0.000 description 4
- XPFUUZJZGOBXTN-UHFFFAOYSA-N C(CNCc1ccc(CN2CCOCC2)cc1)COc(cc1)ccc1-c1nc(ccc(OCCCNCc2ccc(CN3CCOCC3)cc2)c2)c2[o]1 Chemical compound C(CNCc1ccc(CN2CCOCC2)cc1)COc(cc1)ccc1-c1nc(ccc(OCCCNCc2ccc(CN3CCOCC3)cc2)c2)c2[o]1 XPFUUZJZGOBXTN-UHFFFAOYSA-N 0.000 description 2
- YMYJXFUPMPMETB-UHFFFAOYSA-N C(CN1CCCC1)COc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN1CCCC1 Chemical compound C(CN1CCCC1)COc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN1CCCC1 YMYJXFUPMPMETB-UHFFFAOYSA-N 0.000 description 1
- MUUCWDTTXKQBAS-UHFFFAOYSA-N C(CN1CCCCC1)COc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN1CCCCC1 Chemical compound C(CN1CCCCC1)COc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN1CCCCC1 MUUCWDTTXKQBAS-UHFFFAOYSA-N 0.000 description 1
- ZLQGPYGNMGEQMB-KAYWLYCHSA-N CC(C)[C@H]1CN(CCCOc2ccc3nc(-c(cc4)ccc4OCCCN(CC4)C[C@@H]4N(C)C)[o]c3c2)CC1 Chemical compound CC(C)[C@H]1CN(CCCOc2ccc3nc(-c(cc4)ccc4OCCCN(CC4)C[C@@H]4N(C)C)[o]c3c2)CC1 ZLQGPYGNMGEQMB-KAYWLYCHSA-N 0.000 description 1
- TUUYSMSIQQCDGV-JNRHCMNMSA-N CCC(C)[C@H]1CN(CCCOc2ccc3nc(-c(cc4)ccc4OCCCN(CC4)C[C@@H]4N(C)C)[o]c3c2)CC1 Chemical compound CCC(C)[C@H]1CN(CCCOc2ccc3nc(-c(cc4)ccc4OCCCN(CC4)C[C@@H]4N(C)C)[o]c3c2)CC1 TUUYSMSIQQCDGV-JNRHCMNMSA-N 0.000 description 1
- ZDQWTNJTVBWFTO-NRFANRHFSA-N CCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN1[C@H](COC)CCC1 Chemical compound CCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN1[C@H](COC)CCC1 ZDQWTNJTVBWFTO-NRFANRHFSA-N 0.000 description 1
- OQMMQSFGTHNNBZ-UHFFFAOYSA-N CCN(CC)CCNCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCNCCN(CC)CC Chemical compound CCN(CC)CCNCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCNCCN(CC)CC OQMMQSFGTHNNBZ-UHFFFAOYSA-N 0.000 description 1
- JZYRSIGIRMWOLS-UHFFFAOYSA-N CCNCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCNCC Chemical compound CCNCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCNCC JZYRSIGIRMWOLS-UHFFFAOYSA-N 0.000 description 1
- MDBVXDKBQVRJAF-UHFFFAOYSA-N CN(C)CCCN(C)CCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN(C)C Chemical compound CN(C)CCCN(C)CCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCN(C)C MDBVXDKBQVRJAF-UHFFFAOYSA-N 0.000 description 1
- DQWZAGFXJVIOMU-UHFFFAOYSA-N CN1C(COC)CCC1 Chemical compound CN1C(COC)CCC1 DQWZAGFXJVIOMU-UHFFFAOYSA-N 0.000 description 1
- KGHFPRIULSDOQM-UHFFFAOYSA-N COCCNCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCNCCOC Chemical compound COCCNCCCOc(cc1)ccc1-c([o]c1c2)nc1ccc2OCCCNCCOC KGHFPRIULSDOQM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10067808P | 2008-09-26 | 2008-09-26 | |
| US61/100,678 | 2008-09-26 | ||
| PCT/US2009/058398 WO2010036905A1 (en) | 2008-09-26 | 2009-09-25 | Benzoxazole compounds and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504133A JP2012504133A (ja) | 2012-02-16 |
| JP2012504133A5 true JP2012504133A5 (cg-RX-API-DMAC7.html) | 2012-11-01 |
| JP5486602B2 JP5486602B2 (ja) | 2014-05-07 |
Family
ID=41203923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529267A Active JP5486602B2 (ja) | 2008-09-26 | 2009-09-25 | ベンゾオキサゾール化合物および使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8354400B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2350032B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5486602B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010036905A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072891A1 (en) | 2015-03-24 | 2016-09-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | New Toll-Like Receptor 9 Antagonists |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| EP3490983B1 (en) | 2016-07-30 | 2021-02-17 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors |
| US10660877B2 (en) | 2016-09-09 | 2020-05-26 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
| WO2019028302A1 (en) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS |
| KR102688509B1 (ko) | 2017-08-04 | 2024-07-24 | 브리스톨-마이어스 스큅 컴퍼니 | [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 |
| EP3710440B1 (en) | 2017-11-14 | 2023-04-05 | Bristol-Myers Squibb Company | Substituted indole compounds |
| CN107759532B (zh) * | 2017-11-23 | 2021-02-12 | 苏州大学 | 一种苯并噁唑-2-乙基肟衍生物、其制备方法及应用 |
| CN111527080B (zh) | 2017-12-15 | 2023-09-22 | 百时美施贵宝公司 | 取代的吲哚醚化合物 |
| DK3728252T3 (da) | 2017-12-18 | 2023-11-13 | Bristol Myers Squibb Co | 4-azaindolforbindelser |
| CN111491930B (zh) | 2017-12-19 | 2023-09-26 | 百时美施贵宝公司 | 可用作tlr抑制剂的经取代的吲哚化合物 |
| SG11202005704RA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | 6-azaindole compounds |
| SG11202005700SA (en) * | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Amide substituted indole compounds useful as tlr inhibitors |
| US11420958B2 (en) | 2017-12-20 | 2022-08-23 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| CA3086431A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
| MX2020006014A (es) | 2017-12-20 | 2020-08-17 | Bristol Myers Squibb Co | Compuestos de diazaindol. |
| JP7597710B2 (ja) | 2018-10-24 | 2024-12-10 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール二量体の化合物 |
| KR102839382B1 (ko) | 2018-10-24 | 2025-07-25 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 및 인다졸 화합물 |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| WO2020227484A1 (en) | 2019-05-09 | 2020-11-12 | Bristol-Myers Squibb Company | Substituted benzimidazolone compounds |
| EP4041730A1 (en) | 2019-10-01 | 2022-08-17 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| EP4038059B1 (en) | 2019-10-04 | 2023-09-20 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
| WO2022221642A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| US12070455B2 (en) | 2021-09-10 | 2024-08-27 | Gilead Sciences, Inc. | Thienopyrrole compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045539B2 (en) * | 2000-12-22 | 2006-05-16 | Astrazeneca Ab | Therapeutic benzoxazole compounds |
| DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| RU2006110561A (ru) | 2003-09-30 | 2007-10-10 | Янссен Фармацевтика Н.В. (Be) | Соединения бензоимидазола |
| US20060046968A1 (en) | 2004-08-26 | 2006-03-02 | Wyeth | Prodrug substituted benzoxazoles as estrogenic agents |
| CN101351458A (zh) | 2005-12-01 | 2009-01-21 | 匹兹堡大学 | 作为促淀粉样变蛋白成像剂的同位素标记的苯并噻唑化合物 |
-
2009
- 2009-09-25 US US13/121,012 patent/US8354400B2/en active Active
- 2009-09-25 WO PCT/US2009/058398 patent/WO2010036905A1/en not_active Ceased
- 2009-09-25 EP EP09793015.0A patent/EP2350032B1/en active Active
- 2009-09-25 JP JP2011529267A patent/JP5486602B2/ja active Active